"CHI Health Clinic Heart Institute - Grand Island is dedicated to delivering high quality, compassionate care to Grand Island and nearby communities. Visit us at 3515 Richmond Cir or call (308) 381-8636 for more information."

During the past decade, Nebraska Heart Institute- Grand Island conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nebraska Heart Institute- Grand Island" #1 sponsor was "Bayer" with 2 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Brigham and Women's Hospital" with 1 trials sponsored, "Iverson Genetic Diagnostics, Inc." with 1 trials sponsored and "Zoll Medical Corporation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nebraska Heart Institute- Grand Island" #1 collaborator was "Boston VA Research Institute, Inc." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator, "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator and "University of Minnesota" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Nebraska Heart Institute- Grand Island" are "Heart Failure" (4 trials), "Atrial Fibrillation" (2 trials), "Anti-coagulation Therapy" (1 trials), "DVT" (1 trials) and "Joint Surgery Multiple" (1 trials). Many other conditions were trialed in "Nebraska Heart Institute- Grand Island" in a lesser frequency.

Most popular intervention types in "Nebraska Heart Institute- Grand Island" are "Drug" (3 trials), "Device" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nebraska Heart Institute- Grand Island" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Nebraska Heart Institute- Grand Island". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Nebraska Heart Institute- Grand Island, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nebraska Heart Institute- Grand Island, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".